We partnered with EpiMethyl Analytics to tell the story of their groundbreaking work in early cancer detection powered by epigenetics and AI-driven DNA methylation mapping.

Their diagnostic platform analyzes gene methylation patterns from a simple blood test, identifying breast and prostate cancer with over 98% accuracy at any stage of disease. By deeply examining the epigenome, EpiMethyl Analytics is paving the way for faster, more reliable answers for patients, reducing unnecessary procedures, and expanding what’s possible in modern medicine.

In this video, we highlight their completed pilot studies, state-of-the-art facility, and their progress toward FDA approval. With the potential to deploy in as little as 18 months, their technology could fundamentally transform how the world fights cancer.